Ovarian Cancer (Diagnostics)

Forces Joined To Develop Disease Marker

Published in Women's Health Weekly, September 6th, 1999

Atairgin Technologies, Inc., Irvine, California, announced a comprehensive ovarian cancer research collaboration with Northwestern University in Evanston, Illinois, to develop and commercialize Atairgin's LPA test to detect ovarian cancer.

David Fishman, MD, Ovarian Cancer Detection Program at Northwestern University, directs the program that uses Atairgin's platform technology in lysophospholipids to develop an early detection marker for ovarian cancer. When ovarian cancer is detected early, in a localized state, over 90 percent of the women live longer than five years past diagnosis. However, with currently available diagnostics, approximately 70 percent of all...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1999-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry